Commodore Capital L.P. is an investment fund managing more than $622 million ran by Michael Kramarz. There are currently 30 companies in Mr. Kramarz’s portfolio. The largest investments include Cogent Biosciences and Xenon Pharmaceuticals Inc, together worth $122 million.
As of 7th November 2022, Commodore Capital L.P.’s top holding is 4,319,940 shares of Cogent Biosciences currently worth over $64.5 million and making up 10.4% of the portfolio value.
Relative to the number of outstanding shares of Cogent Biosciences, Commodore Capital L.P. owns more than 0.1% of the company.
In addition, the fund holds 1,594,932 shares of Xenon Pharmaceuticals Inc worth $57.6 million, whose value fell approximately 0.1% in the past six months.
The third-largest holding is Viridian Therapeutics Inc worth $55.3 million and the next is Bellus Health Inc worth $54.2 million, with 5,128,557 shares owned.
Currently, Commodore Capital L.P.'s portfolio is worth at least $622 million. The total portfolio value may be much higher due to cash
assets that are not publicly disclosed such as fixed income, real estate, or cash equivalents.
The Commodore Capital L.P. office and employees reside in New York, New York. According to the last 13-F report filed with the SEC, Michael Kramarz serves as the Managing Partner at Commodore Capital L.P..
In the most recent 13F filing, Commodore Capital L.P. revealed that it had opened a new position in
Akero Therapeutics Inc and bought 743,472 shares worth $25.3 million.
This means they effectively own approximately 0.1% of the company.
Akero Therapeutics Inc makes up
5.1%
of the fund's Health Care sector allocation and has decreased its share price by approximately 0.1% in the past year.
The investment fund also strengthened its position in Viridian Therapeutics Inc by buying
1,057,731 additional shares.
This makes their stake in Viridian Therapeutics Inc total 2,696,340 shares worth $55.3 million.
On the other hand, there are companies that Commodore Capital L.P. is getting rid of from its portfolio.
Commodore Capital L.P. closed its position in IVERIC bio Inc on 14th November 2022.
It sold the previously owned 2,409,961 shares for $23.2 million.
Michael Kramarz also disclosed a decreased stake in Cogent Biosciences by 0.1%.
This leaves the value of the investment at $64.5 million and 4,319,940 shares.
The two most similar investment funds to Commodore Capital L.P. are Ausdal Partners and Kays Financial Advisory Corp adv. They manage $622 million and $622 million respectively.
Commodore Capital L.P.’s portfolio is diversified across 2 sectors.
Currently, their heaviest sector is Health Care — making up 80.1% of
the total portfolio value.
The fund focuses on investments in the United States as
60.0% of the portfolio companies
are based in the United States.
The majority of the companies in the fund’s portfolio are small-cap stocks.
Stocks with a size of more than $100 million in market cap make up
10% of the total holdings value.
On the other hand, large-cap stocks make up only approximately 0.1% of the portfolio.
The average market cap of the portfolio companies is close to $846 million.
These positions were updated on November 14th based on the fund’s latest 13F filing. Quickly find out what the most recently closed or increased positions are.
| Security | Shares Owned | Value | Allocation |
|---|---|---|---|
| Cogent Biosciences, Inc. |
12.64%
4,319,940
|
$64,454,000 | 10.36% |
| Xenon Pharmaceuticals Inc |
No change
1,594,932
|
$57,577,000 | 9.26% |
| Viridian Therapeutics Inc |
64.55%
2,696,340
|
$55,302,000 | 8.89% |
| Bellus Health Inc |
14.48%
5,128,557
|
$54,158,000 | 8.71% |
| Merus N.V |
No change
2,615,762
|
$52,394,000 | 8.43% |
| Cytokinetics Inc |
No change
893,646
|
$43,297,000 | 6.96% |
| Aclaris Therapeutics Inc |
No change
2,410,622
|
$37,943,000 | 6.10% |
| Akero Therapeutics Inc |
Opened
743,472
|
$25,315,000 | 4.07% |
| IVERIC bio Inc |
Closed
2,409,961
|
$23,184,000 | |
| Satsuma Pharmaceuticals, Inc. |
No change
3,711,286
|
$22,268,000 | 3.58% |
| Tricida Inc |
2.62%
1,975,403
|
$20,702,000 | 3.33% |
| Cymabay Therapeutics Inc |
No change
5,738,500
|
$20,085,000 | 3.23% |
| Third Harmonic Bio Inc |
Opened
1,018,569
|
$19,322,000 | 3.11% |
| Syndax Pharmaceuticals Inc |
Opened
738,110
|
$17,737,000 | 2.85% |
| Celldex Therapeutics Inc. |
No change
538,812
|
$15,146,000 | 2.44% |
| Day One Biopharmaceuticals I |
No change
739,661
|
$14,815,000 | 2.38% |
| Arrowhead Pharmaceuticals In |
29.29%
404,078
|
$13,355,000 | 2.15% |
| Kura Oncology Inc |
50.76%
899,407
|
$12,286,000 | 1.98% |
| VistaGen Therapeutics Inc |
Closed
13,049,079
|
$11,483,000 | |
| Acumen Pharmaceuticals Inc |
Opened
1,100,000
|
$11,033,000 | 1.77% |
| Karyopharm Therapeutics Inc |
No change
1,935,609
|
$10,568,000 | 1.70% |
| Allakos Inc |
Opened
1,643,500
|
$10,058,000 | 1.62% |
| Alpine Immune Sciences Inc |
Opened
1,325,000
|
$9,540,000 | 1.53% |
| Celcuity Inc |
No change
920,464
|
$9,241,000 | 1.49% |
| Enanta Pharmaceuticals Inc |
Opened
103,494
|
$5,368,000 | 0.86% |
| KalVista Pharmaceuticals Inc |
No change
312,553
|
$4,535,000 | 0.73% |
| Rezolute Inc |
No change
1,210,000
|
$3,315,000 | 0.53% |
| Esperion Therapeutics Inc Ne |
Opened
467,468
|
$3,132,000 | 0.50% |
| Immunic, Inc. |
No change
893,013
|
$2,822,000 | 0.45% |
| Bcls Acquisition Corp |
No change
250,000
|
$2,505,000 | 0.40% |
| Larimar Therapeutics, Inc. |
Opened
750,000
|
$2,400,000 | 0.39% |
| Tenaya Therapeutics Inc |
Closed
357,699
|
$2,014,000 | |
| Terns Pharmaceuticals Inc |
Opened
205,870
|
$1,213,000 | 0.20% |
| Inventiva Sa |
Closed
175,500
|
$995,000 | |
| No transactions found | |||
| Showing first 500 out of 34 holdings | |||